Conditions: Age-related Macular Degeneration
Keywords: Exudative Wet AMD Age-related macular degeneration Age related macular degeneration
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 13
Healthy volunteers: no

Brief summary:
Age-related macular degeneration (AMD) is the leading cause of blindness among adults in North America. The current standard of care for patients with exudative ("wet") AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy which must be administered by an injection into the eye every 4-8 weeks. MT-0814 is being developed for the treatment of patients with exudative AMD, and could offer an alternative, safer and less burdensome therapy.

Detailed description:

Arms:
arm 1: None arm 2: MT-0814 plus placebo arm 3: None

Interventions: intervention 1: MT-0814 intervention 2: Placebo
Intervention descriptions: intervention 1: Randomly assigned dose intervention 2: Placebo manufactured to mimic MT-0814

Protocol document:
Prot_SAP_000.pdf: 
 
 
 
NCT Number: NCT03869684 
 
 
Protocol Number: MT-0814/2-01 
 
 
Study Title: 
A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-
Group Study to Assess the Safety, Tolerability, and Efficacy of MT-0814 for the 
Treatment of Patients with Age-Related Macular Degeneration 
 
 
Protocol Version: Version 4.0: 29 November 2019